G protein-coupled receptors (GPCRs) are currently the most widely focused drug targets in the clinic, exerting their biological functions by binding to chemicals and activating a series of intracellular signaling pathways. Formyl-peptide receptor 1 (FPR1) has a typical seven-transmembrane structure of GPCRs and can be stimulated by a large number of endogenous or exogenous ligands with different chemical properties, the first of which was identified as formyl-methionine-leucyl-phenylalanine (fMLF). Through receptor-ligand interactions, FPR1 is involved in inflammatory response, immune cell recruitment, and cellular signaling regulation in key cell types, including neutrophils, neural stem cells (NSCs), and microglia. This review outlines the critical roles of FPR1 in a variety of heart and brain diseases, including myocardial infarction (MI), ischemia/reperfusion (I/R) injury, neurodegenerative diseases, and neurological tumors, with particular emphasis on the milestones of FPR1 agonists and antagonists. Therefore, an in-depth study of FPR1 contributes to the research of innovative biomarkers, therapeutic targets for heart and brain diseases, and clinical applications.
Keywords: Boc-MLF (PubChem CID: 14655143); Brain; FMLF (PubChem CID: 443295); FPR1; HCH6-1 (PubChem CID: 71697968); Heart; Oligomeric proanthocyanidin (PubChem CID: 122738); Randialic acid B (PubChem CID: 12444674); Tomentosolic acid (PubChem CID: 12315243); fMLF.
Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.